| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02215395 | Antifungal Drug Adverse Reaction | Drug: NES/EE CVR | Population Council | Phase 1 | 2014-03-01 | 2015-04-10 |
| NCT00702507 | Diaper Rash | Drug: 0.25 % Miconazole Nitrate Ointment | Stiefel, a GSK Company|GlaxoSmithKline | Phase 4 | 2007-05-01 | 2012-03-22 |
| NCT01230814 | Bacterial Vaginosis|Candidiasis|Trichomoniasis | Drug: Neo-Penotran Forte (active ingredient Metronidazole & Miconazole Nitrate)|Drug: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2011-04-01 | 2014-09-26 |
| NCT01731574 | HIV | Drug: dapivirine|Drug: miconazole | International Partnership for Microbicides, Inc. | Phase 1 | 2012-12-01 | 2013-11-06 |
| NCT01661556 | Melasma | Drug: Miconazole|Drug: Hydroquinone | Universidad Autonoma de San Luis Potos|Hospital Central "Dr. Ignacio Morones Prieto" | Phase 4 | 2011-10-01 | 2014-12-01 |
| NCT00668538 | Healthy | Drug: Brentan (miconazole) | University of Southern Denmark|Odense University Hospital | | 2008-04-01 | 2008-10-16 |
| NCT01439646 | Antifungal Therapy | Other: it is a retrospective study, hence no active intervention | Fortis Hospital, India|Merck Sharp & Dohme Corp. | | 2011-08-01 | 2015-08-11 |
| NCT00936910 | Central Line Fungal Infections | Drug: amphotericin B liposomal (Ambisome) | University of Pittsburgh|Astellas Pharma Inc | Phase 4 | 2006-09-01 | 2016-01-12 |
| NCT00386802 | Invader Fungal Infection | Drug: Antifungal drug. VORICONAZOL. (VFEND) | PETHEMA Foundation | Phase 4 | 2006-08-01 | 2009-09-17 |
| NCT00390780 | HIV Infections | Drug: miconazole Lauriad|Drug: Clotrimazole | Onxeo | Phase 3 | 2006-07-01 | 2013-09-05 |
| NCT01524432 | Tinea Pedis | Drug: Anti-fungal agent (Clotrimazole) loaded microcapsules|Drug: Placebo | Prof. Yuen Chun-Wah|Dr. Cheung Hing Cheong Private Dermatology Clinic|The Hong Kong Polytechnic University | Phase 1 | 2012-01-01 | 2013-03-31 |
| NCT01686607 | Systemic Fungal Infections | Drug: Parenteral micafungin application|Drug: Other parenteral antifungal drugs | Astellas Pharma Europe B.V.|World Health Information Science Consultants, LLC|Astellas Pharma Inc | 2012-10-01 | 2017-02-28 |
| NCT02154178 | Fungal Infection|Critical Illness | Other: Biomarker group | University Hospital, Lille | | 2014-07-01 | 2017-03-22 |
| NCT01580878 | Tinea Pedis | Drug: Butenafine Hydrochloride Cream, 1%|Drug: Lotrimin Ultra|Drug: Butenafine Vehicle | Taro Pharmaceuticals USA | Phase 1 | 2012-01-01 | 2014-01-19 |
| NCT03090334 | Invasive Candidiases|Abdominal Infection | Diagnostic Test: De-escalation | University of Bologna | | 2017-03-01 | 2017-03-18 |
| NCT00906633 | Fungal Infection | | University Hospital, Udine, Italy|Catholic University of the Sacred Heart | | 2009-01-01 | 2010-01-25 |
| NCT02818803 | Candidiasis, Oral|Stomatitis, Denture | Other: Propolis|Drug: Miconazole | University of Sao Paulo|Financiadora de Estudos e Projetos | Phase 3 | 2016-01-01 | 2016-06-27 |
| NCT02184351 | Candidiasis, Oral | Drug: Roxanes's clotrimazole troches|Drug: Mycelextroches | Boehringer Ingelheim | Phase 3 | 2001-05-01 | 2014-07-11 |
| NCT01769339 | Vulva; Candidiasis | Drug: Miconazole plus Hydrocortisone | Janssen Pharmaceutica | Phase 4 | 2009-01-01 | 2013-02-18 |
| NCT01869829 | Pediatric Invasive Candidiasis | Drug: Observational antifungal therapy | Duke University|Children's Hospital of Philadelphia|National Institute of Allergy and Infectious Diseases (NIAID) | 2013-07-01 | 2016-07-20 |
| NCT00004575 | Healthy | Drug: Miconazole, L-NMMA, Bradykinin | National Heart, Lung, and Blood Institute (NHLBI)|National Institutes of Health Clinical Center (CC) | Phase 1 | 2000-02-01 | 2008-03-03 |
